AngioDynamics (ANGO) Stock Price, News & Analysis

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12 month price objectives for AngioDynamics' stock. Their ANGO share price targets range from $10.00 to $18.00. On average, they anticipate the company's share price to reach $14.25 in the next year. This suggests a possible upside of 127.6% from the stock's current price.
View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts.

AngioDynamics' stock was trading at $7.84 on January 1st, 2024. Since then, ANGO stock has decreased by 20.2% and is now trading at $6.26.
View the best growth stocks for 2024 here.

AngioDynamics saw a drop in short interest in March. As of March 31st, there was short interest totaling 2,250,000 shares, a drop of 8.5% from the March 15th total of 2,460,000 shares. Based on an average daily volume of 575,400 shares, the days-to-cover ratio is presently 3.9 days.
View AngioDynamics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024.
View our ANGO earnings forecast.

AngioDynamics, Inc. (NASDAQ:ANGO) released its earnings results on Wednesday, July, 12th. The medical instruments supplier reported $0.02 EPS for the quarter, meeting analysts' consensus estimates of $0.02. The medical instruments supplier earned $91.10 million during the quarter, compared to the consensus estimate of $90.73 million. AngioDynamics had a negative trailing twelve-month return on equity of 3.48% and a negative net margin of 60.21%. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.01 EPS.

Invesco Nasdaq Future Gen 200 ETF holds 7,477 shares of ANGO stock, representing 0.65% of its portfolio.

AngioDynamics updated its FY 2024 earnings guidance on Thursday, April, 4th. The company provided earnings per share guidance of -0.580--0.540 for the period, compared to the consensus EPS estimate of -0.430. The company issued revenue guidance of $270.0 million-$275.0 million, compared to the consensus revenue estimate of $312.1 million.

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

AngioDynamics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends.

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.